Since therapy-resistant mesenchymal-high cancers have increased vulnerability to ferroptosis inducers, especially GPx4 inhibitors5,6, and MTDH promotes EMT and treatment resistance, we therefore investigated whether MTDH confers enhanced vulnerability to ferroptosis. The gene discussed is MTDH; the disease is cancer.